Form D · Biotechnology
Thrasos Innovation Inc.
Montreal, A8 · CIK 0001637636
Offering snapshot reported Mar 25, 2015 · SEC filing
- Reported sold
- $14M Offering amount: $21M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 12, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2015 | Initial | $14,000,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-236626
Source: Form D, filed Mar 25, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Andrews | Director, Executive |
| Raphaela (Ela) Borenstein | Director |
| Jens Eckstein | Director |
| Jean George | Director |
| Gaetan Gravel | Director |
| Daniel Hetu | Director |
| Donald Notman | Executive |
| Jonathan Wener | Director |
| Joseph Zakrzewski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7171 Frederick Banting
Montreal, A8, H4S 1Z9
Montreal, A8, H4S 1Z9